Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
27 April 2021 - 10:35PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced data from its fusogen technology platform, which are
being presented at the virtual American Society of Gene & Cell
Therapy (ASGCT) Annual Meeting 2021.
The data to be presented demonstrate in vivo gene delivery to T
cells and hepatocytes using a re-targetable fusogen delivery
method. Sana is developing fusogens as a platform technology to
enable the delivery of genetic payloads to specific cell types.
Fusogens can bind to cell-surface proteins on the target cell type
and then deliver the genetic payload directly to the cell’s
cytoplasm. The reliable and efficient delivery of genetic payloads
to specific cell types is considered a key obstacle in achieving
safe and effective in vivo gene modification.
“These early data are encouraging by showing that our fusogen
platform can not only target specific and varying cell types but
also demonstrate tumor cell killing and eradication both in vitro
and in vivo,” said Sunil Agarwal, Sana’s Head of Development and
Chief Medical Officer. “The potential for fusogens to target and
deliver therapies to CD4 T cells, CD8 T cells, and hepatocytes in
vivo highlights the scope of our technologies beyond a single cell
type or disease. Though preliminary, developing optimized fusogens
represents an important step toward increasing gene therapy options
for patients with various cancers and genetic diseases.”
Data on the fusogen platform were outlined in the abstract for
the poster presentation and made available to the public online
today. The full poster will be available to ASGCT conference
participants beginning Tuesday, May 11 at 6:00 a.m. Eastern
Time.
In vivo gene delivery to T cells and
hepatocytes achieved through a re-targetable fusogen
platformAuthors: Jagesh Shah, PhD, et al.
Key takeaways include:
- For T cells, CD8-targeted fusogens showed cell-specific
selectivity and efficient in vitro and in vivo gene transduction,
leading to demonstrable dose-dependent in vivo tumor
eradication.
- For liver cells, hepatocyte-targeted fusogens showed
specificity for hepatocyte cell-surface proteins and efficient
transduction in both engineered cell lines and human
hepatocytes.
- These experimental results demonstrate the potential of
fusogen-targeted vectors to deliver genes efficiently and with cell
specificity in vivo, opening pathways to future gene therapies for
a diverse set of diseases.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are more than 280
people working together to create an enduring company that changes
how the world treats disease. Sana has operations in Seattle,
Cambridge, and South San Francisco. For more information about Sana
Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to Sana’s mission and progress, the ability
to deliver genetic payloads in vivo to specific cell types reliably
and efficiently, the ability to increase gene therapy options for
patients, and posters at ASGCT. All statements other than
statements of historical facts contained in this press release,
including, among others, statements regarding the Company’s
strategy, expectations, cash runway and future financial condition,
future operations, and prospects, are forward-looking statements.
In some cases, you can identify forward-looking statements by
terminology such as “aim,” “anticipate,” “assume,” “believe,”
“contemplate,” “continue,” “could,” “design,” “due,” “estimate,”
“expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results to vary materially, including, among others, the
risks inherent in drug development such as those associated with
the initiation, cost, timing, progress and results of the Company’s
current and future research and development programs, preclinical
and clinical trials. For a detailed discussion of the risk factors
that could affect the Company’s actual results, please refer to the
risk factors identified in the Company’s SEC reports, including but
not limited to its Annual Report on Form 10-K dated March 24, 2021.
Except as required by law, the Company undertakes no obligation to
update publicly any forward-looking statements for any reason.
Investor Relations:Nicole
Keithinvestor.relations@sana.com
Media:Morgan Warners, Finsbury Glover
Heringmedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jul 2023 bis Jul 2024